Chickasaw Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Chickasaw Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-49,000	Closed	-$1.63M	–	105
2017 Q2	$1.63M	Hold	49,000	–	–	0.03%	53
2017 Q1	$1.57M	Hold	49,000	–	–	0.03%	52
2016 Q4	$1.78M	Buy	49,000 +2,000	+4%	+$79.9K	0.04%	49
2016 Q3	$2.16M	Hold	47,000	–	–	0.05%	41
2016 Q2	$2.36M	Hold	47,000	–	–	0.06%	39
2016 Q1	$2.52M	Hold	47,000	–	–	0.08%	37
2015 Q4	$3.08M	Hold	47,000	–	–	0.1%	41
2015 Q3	$2.65M	Hold	47,000	–	–	0.1%	41
2015 Q2	$2.78M	Hold	47,000	–	–	0.08%	42
2015 Q1	$2.93M	Hold	47,000	–	–	0.09%	43
2014 Q4	$2.7M	Hold	47,000	–	–	0.09%	47
2014 Q3	$2.53M	Hold	47,000	–	–	0.08%	45
2014 Q2	$2.46M	Hold	47,000	–	–	0.09%	45
2014 Q1	$2.48M	Hold	47,000	–	–	0.12%	47
2013 Q4	$1.88M	Hold	47,000	–	–	0.1%	53
2013 Q3	$1.78M	Buy	47,000 +2,000	+4%	+$78K	0.12%	52
2013 Q2	$1.76M	Buy	+45,000	New	+$1.75M	0.13%	48

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Chickasaw Capital Management's TEVA Position: Q3 2017 in Review

Chickasaw Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 49,000 shares — an estimated $1.63M sold.

Chickasaw Capital Management first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $3.08M in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

Chickasaw Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
Chickasaw Capital Management sold 49,000 Teva Pharmaceuticals shares in Q3 2017, an estimated $1.63M.
Chickasaw Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
Chickasaw Capital Management's Teva Pharmaceuticals position peaked at $3.08M in Q4 2015.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on Chickasaw Capital Management's 13F filing for Q3 2017, filed 16 Oct 2017.